Pricing
  1. US-listed companies
  2. Edesa Biotech, Inc.
  3. Raw

Edesa Biotech, Inc.【EDSA】

Market cap
$35.96M
P/E ratio
SummaryFinancials
Back to summarized table
Sep 30,
2015		Sep 30,
2016		Sep 30,
2017		Sep 30,
2018		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022		Sep 30,
2023		Sep 30,
2024
Cash and cash equivalents------751
Accounts and other receivable------1626,543270,908
Prepaid expenses and other current assets----802,877948,645745,543448,912367,394
Total current assets1012711812962
Property and equipment, net503,408756,114879,523114,81514,98912,6948,702-
Long-term deposits15,90015,34015,34015,340---173,49041,151
Intangible asset, net----22-22
Right-of-use assets----160,00696,57118,46591,37318,361
Total assets101381211151294
Accounts payable and accrued liabilities656,685623,644320,947493,38511222
Short-term right-of-use lease liabilities----69,73078,80818,97574,71419,867
Total current liabilities2623,644320,947493,38521222
Long-term right-of-use lease liabilities----94,46020,512-19,773-
Total liabilities2---22222
Authorized unlimited common and preferred shares without par value issued and outstanding: 3,247,389 common shares (September 30, 2023 - 3,075,473)384748571935--47
Additional paid-in capital----25111314
Accumulated other comprehensive loss-----287,204-205,262-213,602-214,648-242,613
Accumulated deficit-35,335,315-40,361,395-45,392,043-50,430,992-13,132,954-26,495,629-44,044,553-52,418,968-59
Total shareholders' equity812711713972
Total liabilities and shareholders' equity101381211151294